SI1146874T1 - Vitronectin receptor antagonist - Google Patents

Vitronectin receptor antagonist

Info

Publication number
SI1146874T1
SI1146874T1 SI9930700T SI9930700T SI1146874T1 SI 1146874 T1 SI1146874 T1 SI 1146874T1 SI 9930700 T SI9930700 T SI 9930700T SI 9930700 T SI9930700 T SI 9930700T SI 1146874 T1 SI1146874 T1 SI 1146874T1
Authority
SI
Slovenia
Prior art keywords
receptor antagonist
vitronectin receptor
vitronectin
antagonist
receptor
Prior art date
Application number
SI9930700T
Other languages
English (en)
Slovenian (sl)
Inventor
William H. Miller
Peter J. Manley
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of SI1146874T1 publication Critical patent/SI1146874T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
SI9930700T 1998-12-04 1999-12-03 Vitronectin receptor antagonist SI1146874T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11090398P 1998-12-04 1998-12-04
PCT/US1999/028662 WO2000033838A1 (en) 1998-12-04 1999-12-03 Vitronectin receptor antagonist
EP99960647A EP1146874B1 (de) 1998-12-04 1999-12-03 Vitronectin rezeptor antagonist

Publications (1)

Publication Number Publication Date
SI1146874T1 true SI1146874T1 (en) 2005-04-30

Family

ID=22335565

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9930700T SI1146874T1 (en) 1998-12-04 1999-12-03 Vitronectin receptor antagonist

Country Status (39)

Country Link
US (1) US6495560B1 (de)
EP (1) EP1146874B1 (de)
JP (1) JP4481504B2 (de)
KR (1) KR100620485B1 (de)
CN (1) CN1147300C (de)
AP (1) AP1534A (de)
AR (1) AR035006A1 (de)
AT (1) ATE277043T1 (de)
AU (1) AU754408B2 (de)
BG (1) BG65118B1 (de)
BR (1) BR9915879A (de)
CA (1) CA2353415A1 (de)
CO (1) CO5150166A1 (de)
CZ (1) CZ20011963A3 (de)
DE (1) DE69920518T2 (de)
DK (1) DK1146874T3 (de)
DZ (1) DZ2954A1 (de)
EA (1) EA003254B1 (de)
EG (1) EG24025A (de)
ES (1) ES2229798T3 (de)
HK (1) HK1042037B (de)
HU (1) HUP0104804A3 (de)
ID (1) ID28811A (de)
IL (2) IL143390A0 (de)
MA (1) MA25265A1 (de)
NO (1) NO318895B1 (de)
NZ (1) NZ511876A (de)
OA (1) OA11724A (de)
PE (1) PE20001563A1 (de)
PL (1) PL195973B1 (de)
PT (1) PT1146874E (de)
SI (1) SI1146874T1 (de)
SK (1) SK7452001A3 (de)
TR (1) TR200101654T2 (de)
TW (1) TW482673B (de)
UA (1) UA71586C2 (de)
UY (1) UY25824A1 (de)
WO (1) WO2000033838A1 (de)
ZA (1) ZA200104398B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001269821A1 (en) * 2000-06-15 2001-12-24 Barbara Chen Cycloalkyl alkanoic acids as integrin receptor antagonists
DE60118025T2 (de) * 2000-10-24 2006-11-23 Merck & Co., Inc. Dibenzoxazepin-alpha-v-integrin-rezeptorantagonist
NZ539682A (en) 2001-01-29 2006-03-31 Dimensional Pharm Inc Substituted indoles and their use as integrin antagonists
US6872730B2 (en) 2001-04-27 2005-03-29 3-Dimensional Pharmaceuticals, Inc. Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
WO2004058760A1 (en) 2002-12-20 2004-07-15 Pharmacia Corporation Thiazole compounds as integrin receptor antagonists derivatives
GB0319069D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Therapeutically useful compounds
JP2008524334A (ja) * 2004-12-21 2008-07-10 スミスクライン・ビーチャム・コーポレイション 方法および処方
KR101491938B1 (ko) 2010-07-14 2015-02-10 노파르티스 아게 Ｉｐ 수용체 효능제 헤테로시클릭 화합물
WO2013105057A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused pyrroles as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
WO2014125413A1 (en) 2013-02-13 2014-08-21 Novartis Ag Ip receptor agonist heterocyclic compounds
HRP20211836T1 (hr) 2013-09-24 2022-03-04 Fujifilm Corporation Novi spoj koji sadrži dušik ili njegova sol, ili njegov metalni kompleks

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2687154B1 (fr) 1992-02-07 1995-05-12 Rhone Poulenc Rorer Sa Nouveau derive de l'isoindolinone, sa preparation et les compositions pharmaceutiques qui le contiennent.
DE69627899T2 (de) * 1995-06-29 2004-05-19 Smithkline Beecham Corp. Integrin-rezeptor-antagonisten
WO1998013278A1 (de) * 1996-09-27 1998-04-02 Merkler, H. Tank für flüssigkeiten, insbesondere für chemisch aggressive flüssigkeiten
JP2001501951A (ja) * 1996-10-07 2001-02-13 スミスクライン・ビーチャム・コーポレイション 骨形成刺激方法
UY24949A1 (es) 1997-04-08 2001-04-30 Smithkline Beecham Corp Compuestos calcilíticos

Also Published As

Publication number Publication date
TR200101654T2 (tr) 2002-03-21
AP1534A (en) 2006-01-09
KR100620485B1 (ko) 2006-09-13
UY25824A1 (es) 2001-07-31
EG24025A (en) 2008-03-26
PL195973B1 (pl) 2007-11-30
HUP0104804A3 (en) 2002-12-28
AR035006A1 (es) 2004-04-14
CO5150166A1 (es) 2002-04-29
HUP0104804A2 (hu) 2002-05-29
ZA200104398B (en) 2002-05-29
WO2000033838A1 (en) 2000-06-15
PT1146874E (pt) 2005-02-28
HK1042037A1 (en) 2002-08-02
JP2003523931A (ja) 2003-08-12
PL348702A1 (en) 2002-06-03
JP4481504B2 (ja) 2010-06-16
NZ511876A (en) 2004-02-27
ES2229798T3 (es) 2005-04-16
NO20012732L (no) 2001-08-01
EP1146874B1 (de) 2004-09-22
ID28811A (id) 2001-07-05
DZ2954A1 (fr) 2004-06-20
EP1146874A1 (de) 2001-10-24
ATE277043T1 (de) 2004-10-15
NO20012732D0 (no) 2001-06-01
US6495560B1 (en) 2002-12-17
CN1147300C (zh) 2004-04-28
CN1334730A (zh) 2002-02-06
BG105651A (en) 2002-02-28
EA200100618A1 (ru) 2001-12-24
DK1146874T3 (da) 2005-01-31
EA003254B1 (ru) 2003-02-27
AU754408B2 (en) 2002-11-14
DE69920518D1 (de) 2004-10-28
HK1042037B (zh) 2005-07-29
MA25265A1 (fr) 2001-10-01
SK7452001A3 (en) 2001-12-03
IL143390A0 (en) 2002-04-21
UA71586C2 (en) 2004-12-15
PE20001563A1 (es) 2001-02-09
CA2353415A1 (en) 2000-06-15
DE69920518T2 (de) 2005-09-22
TW482673B (en) 2002-04-11
EP1146874A4 (de) 2002-06-05
KR20010080669A (ko) 2001-08-22
CZ20011963A3 (cs) 2001-11-14
BR9915879A (pt) 2002-02-13
IL143390A (en) 2006-07-05
OA11724A (en) 2005-01-26
BG65118B1 (bg) 2007-03-30
NO318895B1 (no) 2005-05-18
AU1750200A (en) 2000-06-26

Similar Documents

Publication Publication Date Title
EP1000031A4 (de) Vitronectinrezeptor-antagonist
IL142958A0 (en) Vitronectin receptor antagonist pharmaceuticals
CY2576B1 (en) Vitronectin receptor antagonists
ZA9896B (en) Vitronectin receptor antagonists
IL138245A0 (en) Vitronectin receptor antagonists
IL135189A0 (en) Vitronectin receptor antagonist
IL135188A0 (en) Vitronectin receptor antagonist
IL135028A0 (en) Vitronectin receptor antagonists
EG24025A (en) Vitronectin receptor antagonist
EG24179A (en) Vitronectin receptor antagonists
IL141163A0 (en) Vitronectin receptor antagonists
GB9810882D0 (en) Vitronectin receptor antagonists
GB9812686D0 (en) Vitronectin receptor antagonists
GB9807382D0 (en) Vitronectin receptor antagonists
GB9822331D0 (en) Vitronectin receptor antagonists
GB9815803D0 (en) Vitronectin receptor antagonists
GB9810182D0 (en) Vitronectin receptor antagonists
GB9811295D0 (en) Vitronectin receptor antagonists
GB9807384D0 (en) Vitronectin receptor antagonists
GB9810892D0 (en) Vitronectin receptor antagonists
SI1140203T1 (sl) Viktronektin receptor farmacevtski antagonist
ZA988562B (en) Vitronectin receptor antagonists
ZA991884B (en) Vitronectin receptor antagonists.
GB9811283D0 (en) Vironectin receptor antagonists
SI0957917T1 (sl) Antagonisti receptorja vitronektina